OptiBiotix Health’s (OPTI) Corporate Rating Reaffirmed at FinnCap

OptiBiotix Health (LON:OPTI)‘s stock had its “corporate” rating restated by investment analysts at FinnCap in a report issued on Tuesday.

LON OPTI opened at GBX 83 ($1.08) on Tuesday. OptiBiotix Health has a 12-month low of GBX 54.30 ($0.71) and a 12-month high of GBX 90 ($1.18).

In other OptiBiotix Health news, insider Neil Davidson bought 103,000 shares of OptiBiotix Health stock in a transaction that occurred on Monday, July 30th. The stock was purchased at an average price of GBX 99 ($1.29) per share, with a total value of £101,970 ($133,241.87).

About OptiBiotix Health

Optibiotix Health Plc, a life sciences company, engages in the research and development of microbiome modulators primarily in the United Kingdom. The company is developing microbial strains, compounds, and formulations, which modulates the human microbiome and impacts lipid and cholesterol management, energy harvest, and appetite suppression activities.

Further Reading: Penny Stocks

Receive News & Ratings for OptiBiotix Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiBiotix Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply